What do systematic reviews say?

Gestrinone vs danazol

It is very uncertain whether gestrinone changes side effects: hot flushes compared with danazol (very low certainty).

• Progesterone receptor modulators for endometriosis 2017 · Cochrane Headline outcomes only
  OR 0.79 [0.5, 1.26]
  2 studies · 302 participants
  Very low

Gestrinone vs danazol

Gestrinone showed no clear difference in side effects: acne compared with danazol (low certainty).

• Progesterone receptor modulators for endometriosis 2017 · Cochrane Headline outcomes only
  OR 1.45 [0.9, 2.33]
  2 studies · 302 participants
  Low

Gestrinone vs leuprolin

• Progesterone receptor modulators for endometriosis 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 55 participants
  Low

Gestrinone vs leuprolin

• Progesterone receptor modulators for endometriosis 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 52 participants
  Low

Gestrinone vs leuprolin

Gestrinone may leads to lower amenorrhoea compared with leuprolin (low certainty).

• Progesterone receptor modulators for endometriosis 2017 · Cochrane Headline outcomes only
  OR 0.04 [0.01, 0.38]
  1 study · 49 participants
  Low

Gestrinone vs leuprolin

Gestrinone may leads to higher spotting or bleeding compared with leuprolin (low certainty).

• Progesterone receptor modulators for endometriosis 2017 · Cochrane Headline outcomes only
  OR 22.92 [2.64, 198.66]
  1 study · 49 participants
  Low

Gestrinone vs leuprolin

Gestrinone may leads to lower side effects: hot flushes compared with leuprolin (low certainty).

• Progesterone receptor modulators for endometriosis 2017 · Cochrane Headline outcomes only
  OR 0.2 [0.06, 0.63]
  1 study · 55 participants
  Low

Mifepristone (all doses) vs placebo

Mifepristone may leads to lower prevalence of dyspareunia compared with placebo (low certainty).

• Progesterone receptor modulators for endometriosis 2017 · Cochrane Headline outcomes only
  OR 0.23 [0.1, 0.51]
  1 study · 223 participants
  Low

Mifepristone (all doses) vs placebo

Mifepristone leads to higher side effects: amenorrhoea compared with placebo (high certainty).

• Progesterone receptor modulators for endometriosis 2017 · Cochrane Headline outcomes only
  OR 686.16 [92.29, 5101.33]
  1 study · 360 participants
  High

Mifepristone (all doses) vs placebo

Mifepristone leads to higher side effects: hot flushes compared with placebo (high certainty).

• Progesterone receptor modulators for endometriosis 2017 · Cochrane Headline outcomes only
  OR 28.79 [3.93, 210.73]
  1 study · 360 participants
  High

Gestrinone vs danazol

It is very uncertain whether gestrinone changes pelvic pain: none or mild compared with danazol (very low certainty).

• Progesterone receptor modulators for endometriosis 2017 · Cochrane Headline outcomes only
  OR 0.71 [0.33, 1.56]
  2 studies · 230 participants
  Very low

Gestrinone vs danazol

It is very uncertain whether gestrinone changes dysmenorrhoea: none or mild compared with danazol (very low certainty).

• Progesterone receptor modulators for endometriosis 2017 · Cochrane Headline outcomes only
  OR 0.72 [0.39, 1.33]
  2 studies · 214 participants
  Very low

Gestrinone vs danazol

It is very uncertain whether gestrinone changes dyspareunia: none or mild compared with danazol (very low certainty).

• Progesterone receptor modulators for endometriosis 2017 · Cochrane Headline outcomes only
  OR 0.83 [0.37, 1.86]
  2 studies · 222 participants
  Very low

Gestrinone vs danazol

It is very uncertain whether gestrinone changes side effects: hirsutism compared with danazol (very low certainty).

• Progesterone receptor modulators for endometriosis 2017 · Cochrane Headline outcomes only
  OR 2.63 [1.6, 4.32]
  2 studies · 302 participants
  Very low

Gestrinone vs danazol

Gestrinone may leads to lower decreased breast size compared with danazol (low certainty).

• Progesterone receptor modulators for endometriosis 2017 · Cochrane Headline outcomes only
  OR 0.62 [0.38, 0.98]
  2 studies · 302 participants
  Low

SPRM vs placebo

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 171 participants
  Moderate

SPRM vs leuprolide acetate

SPRM showed no clear difference in abnormal uterine bleeding: amenorrhoea compared with leuprolide acetate (moderate certainty).

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  OR 1.14 [0.6, 2.16]
  1 study · 280 participants
  Moderate

SPRM vs leuprolide acetate

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 281 participants
  Moderate

SPRM vs leuprolide acetate

SPRM probably leads to higher adverse effects: SPRM‐associated endometrial changes compared with leuprolide acetate (moderate certainty).

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  OR 10.45 [5.38, 20.33]
  1 study · 301 participants
  Moderate

SPRM vs placebo

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 200 participants
  Moderate